Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Should you buy or sell ALLO stock after shares plunge 37% as FDA halts clinical trial?
05:56pm, Thursday, 07'th Oct 2021
On Thursday, Allogene Therapeutics Inc. (NASDAQ:ALLO) shares plummeted by more than 37% in the after-hours session after the US Food and Drug Administration (FDA) put on hold the clinical trial for Al
Allogene Therapeutics stock halted as FDA puts hold on cancer drug study
04:44pm, Thursday, 07'th Oct 2021
Allogene Therapeutics Inc. ALLO, +1.71% shares were halted in the extended session Thursday after the biotech drug developer said the Food and Drug Administration placed a hold on the company's cancer
Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial
04:15pm, Thursday, 07'th Oct 2021
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board
08:30am, Monday, 20'th Sep 2021
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
Allogene Therapeutics (ALLO) Up 9.6% Since Last Earnings Report: Can It Continue?
01:00pm, Friday, 03'rd Sep 2021
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
08:30am, Wednesday, 01'st Sep 2021
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
Allogene's (ALLO) CAR T Therapy Gets Orphan Drug Status
01:09pm, Friday, 13'th Aug 2021
Allogene's (ALLO) CAR T therapy, ALLO-715, gets orphan-drug designation in the United States. It is a potential treatment for multiple myeloma and other BCMA-positive malignancies.
Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)
08:30am, Thursday, 12'th Aug 2021
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene (ALLO) Q2 Earnings Top, Sales Lag, Pipeline Advances
11:25am, Thursday, 05'th Aug 2021
Allogene (ALLO) beats earnings estimates but misses the same for revenues in the second quarter.
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2021 Results - Earnings Call Transcript
10:36pm, Wednesday, 04'th Aug 2021
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2021 Results - Earnings Call Transcript
Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors
08:30am, Monday, 02'nd Aug 2021
Collective Expertise in Strategic Development and Commercialization Will Guide Preparation of the Industry's First Potentially Pivotal Allogeneic CAR T Trial and Launch Collective Expertise in Strateg
Allogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021
08:30am, Tuesday, 27'th Jul 2021
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET
Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
08:30am, Monday, 12'th Jul 2021
SOUTH SAN FRANCISCO, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene (ALLO) Multiple Myeloma Candidate Gets Fast Track Tag
12:02pm, Thursday, 01'st Jul 2021
Allogene's (ALLO) next-generation allogeneic CAR T therapy, ALLO-605, gets Fast Track designation from the FDA to treat patients with relapsed or refractory multiple myeloma.
SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
